XML 22 R37.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Legal Proceedings, Commitments and Contingencies Details (Details) (USD $) In Thousands, except Share data, unless otherwise specified | 0 Months Ended | 9 Months Ended
--- | --- | ---
Jan. 13, 2014 | Sep. 30, 2014 | Sep. 30, 2013
Loss Contingencies [Line Items] |  |  |
Payments to Acquire Businesses, Gross | $ 2,000 | $ 2,315 | $ 0
Mills Pharamaceuticals Milestone 1 |  | 2,000,000 |
Mills Pharamaceuticals Milestone 2 |  | 2,000,000 |
Mills Pharmaceuticals Maximum Shares Issuable for Milestones |  | 3,000,000 |
Mills Pharmaceuticals - Price per share floor |  | $ 4.84 |
Mills Pharmaceuticals - price per share ceiling |  | $ 6.84 |
Closing price of the Company's common stock |  | $ 4.84 |
Issuance of common stock for milestone payment |  | 6,840 |
Common Stock [Member] |  |  |
Loss Contingencies [Line Items] |  |  |
Issuance of common stock for milestone payment, other |  | 3,000,000 |
Additional Paid-in Capital [Member] |  |  |
Loss Contingencies [Line Items] |  |  |
Issuance of common stock for milestone payment |  | $ 6,840 |

X
- Definition Closing price of common stock. + References No definition available. + Details
Name: | gale_ClosingPriceOfCommonStock
Namespace Prefix: | gale_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Mills Pharamaceuticals Milestone 1 - 2,000,000 shares of our common stock upon initiating the first clinical trial of GALE-401. + References No definition available. + Details
Name: | gale_MillsPharamaceuticalsMilestone1
Namespace Prefix: | gale_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Mills Pharamaceuticals Milestone 2 - upon initiating the Phase 3 clinical trial in GALE-401 + References No definition available. + Details
Name: | gale_MillsPharamaceuticalsMilestone2
Namespace Prefix: | gale_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Mills Pharmaceuticals Maximum Shares Issuable for Milestones + References No definition available. + Details
Name: | gale_MillsPharmaceuticalsMaximumSharesIssuableforMilestones
Namespace Prefix: | gale_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Mills Pharmaceuticals - price per share ceiling - The number of shares issuable upon the milestones is subject to increase based on a formula specified in the purchase agreement, up to a maximum of 3,000,000 shares for each milestone, in the event the five‑day average trailing closing price of our common stock (the “Average Price”) is less than $4.84 at the time the applicable milestone is achieved. Similarly, the number of shares issuable upon achievement of the milestones is subject to decrease based on such formula if the Average Price exceeds $6.84 at the time of achievement of the applicable milestone. + References No definition available. + Details
Name: | gale_MillsPharmaceuticalspricepershareceiling
Namespace Prefix: | gale_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Mills Pharmaceuticals - Price per share floor - The number of shares issuable upon the milestones is subject to increase based on a formula specified in the purchase agreement, up to a maximum of 3,000,000 shares for each milestone, in the event the five‑day average trailing closing price of our common stock (the “Average Price”) is less than $4.84 at the time the applicable milestone is achieved. Similarly, the number of shares issuable upon achievement of the milestones is subject to decrease based on such formula if the Average Price exceeds $6.84 at the time of achievement of the applicable milestone. + References No definition available. + Details
Name: | gale_MillsPharmaceuticalsPricepersharefloor
Namespace Prefix: | gale_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesOther
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValueOther
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration